President and Chief Executive Officer
Dr. Seely is an endocrinologist with over 20 years of drug development and biopharmaceutical company leadership experience. At Medivation, she served as Chief Medical Officer from 2005-2015 and led the development of XTANDI® (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer from IND-enabling studies through to NDA approval and post-approval clinical studies. Dr. Seely currently serves on the Board of Directors of Blueprint Medicines Corporation. She completed her residency in internal medicine at Yale-New Haven Hospital and a basic science and clinical fellowship in endocrinology and metabolism at the University of California, San Diego.
Chief Financial Officer
Mr. Karbe previously served as Executive Vice President and Chief Financial Officer for Exelixis from 2004-2014. Earlier in his career, he worked as an investment banker for Goldman Sachs & Co., where he served most recently as Vice President in the healthcare group focusing on corporate finance and mergers and acquisitions in the biotechnology industry. He also previously served as President of The Color Run, a global mass participation events platform and on the Board of Directors of Arbutus Biopharma Corporation and Kolltan Pharmaceuticals, Inc. He received his Diplom-Kaufmann from the WHU-Otto Beisheim Graduate School of Management, Koblenz, Germany.
Chief Medical Officer
Dr. Arjona Ferreira was previously Senior Vice President, Clinical Development at Shionogi Inc. At Shionogi, Dr. Arjona Ferreira was responsible for leading the company’s US Clinical Development organization and he served on the company’s US Senior Leadership Team and the Global Scientific Committee. Prior to joining Shionogi, Dr. Arjona Ferreira spent over a decade at Merck & Co. where he was Executive Director of Clinical Research in Women’s Health. At Merck, he chaired the product development teams for all programs in contraception and women’s health. Dr. Arjona Ferreira earned his MD and completed his postgraduate specialist training in Obstetrics and Gynecology at Colegio Mayor del Rosario in Bogota, Colombia.
Chief Commercial Officer
Ms. Sablich was previously Vice President, Primary Care Marketing in the US for Glaxo SmithKline (GSK) where she was responsible for revenue forecasts, product strategies, and execution plans for a broad portfolio of products Advair®, Breo, Anoro®, Incruse®, Tanzeum™, Levitra®, and Trelegy. She earlier served as Vice President, Global Medicines Commercialization in the UK, and before that was Vice President, Vaccines Commercial Strategies. Before joining GSK, Ms. Sablich spent 15 years at Merck where she held positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory, and vaccines business areas. Ms. Sablich has extensive experience in direct-to-consumer marketing, having led the development of consumer strategies and national multi-channel campaigns for multiple products. She currently serves on the Board of Directors of AllerGenis LLC. Ms. Sablich earned her BA degree from Denison University and her MBA from The Wharton School of the University of Pennsylvania.
General Counsel and Corporate Secretary
Mr. Lang was previously Vice President, Head of Global Litigation, Investigations, Employment Law and Information Governance at Gilead Sciences, Inc. At Gilead, in addition to leading core functions within the legal department, Mr. Lang was a member of the company’s Corporate Operating Group, Global Legal Leadership Team, and Global Compliance Committee. Prior to Gilead, Mr. Lang was an attorney at Dechert LLP in New York City. Mr. Lang received his BA in Classical Studies from Queen’s University in Canada and his JD from the University of Pennsylvania Law School.
Senior Vice President, Pharmaceutical Operations and Development
Mr. Nornhold previously served as Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.) from 2014-2018, and was responsible for the Company's manufacturing, supply chain, quality and technical operations. Jeff served as Impax’s Senior Vice President, Global Quality Affairs from 2011-2014 and was responsible for establishing a sustainable quality and compliance program. Prior to Impax, Jeff served as Vice President, Quality Operations – International for Watson Pharmaceuticals, Inc. (now Allergan PLC), and was responsible for ex-U.S. manufacturing sites for both dosage and active pharmaceutical ingredients. While at Watson, he also served as Vice President, U.S. Quality Operations leading the development and execution of quality initiatives for all U.S. sites. Earlier in his career he held numerous leadership positions within the pharmaceutical industry. Mr. Nornhold earned a BS degree in chemistry from Bowling Green State University and an MBA from the University of Southern California Marshall School of Business.
Senior Vice President, Regulatory Affairs and Quality Assurance
Dr. Perney was previously Medicine Team Leader for XTANDI® and talazoparib at Pfizer, Inc. Prior to Pfizer, Dr. Perney held positions of increasing responsibility within regulatory affairs at several pharmaceutical companies, including Medivation, Inc., Hoffman-La Roche/Genentech, Inc., and Schering-Plough Corporation. She has global regulatory experience in multiple therapeutic areas including oncology, cardiovascular, metabolic diseases, immunology, and respiratory diseases. Dr. Perney received her BA in Biology from Northwestern University and her PhD in Neurobiology from the University of Chicago.
Senior Vice President, Product Development
Mr. Selby has more than two decades of pharma and biotech industry experience. Previously, he worked at Medivation from 2007-2016, where he served most recently as Senior Vice President, Product Strategy. There he provided oversight for the development programs for investigational oncology products talazoparib and pidilizumab and oversaw the acquisition of products, technologies and companies for Medivation’s clinical pipeline. He also played a key leadership role in the development of XTANDI® (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer. Earlier in his career, he held roles at Alza/J&J, Nuvelo, Corgentech and Gilead Sciences. He received his MS in statistics from Kansas State University and his BA in mathematics from Washburn University.
Vice President, Human Resources
Ms. Tran has approximately 20 years of HR experience at both large global enterprises and small emerging companies and has worked with business leaders, managers and HR partners on the execution of a broad range of HR projects. Previously, she held roles at Raptor Pharmaceuticals, Johnson & Johnson, Medivation and Ipsen. She received her MBA and MS in human resources management from Golden Gate University and a BA in communication studies from San Jose State University.